布鲁顿的氨酸激酶抑制剂用于多发性硬化症治疗:一个新的前沿
1Department of Neurology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.
Neurologic clinics
|November 18, 2023
概括
布鲁顿的氨酸激酶 (BTK) 抑制剂通过向炎症和B细胞激活,为多发性硬化症 (MS) 提供了一种新的治疗方法. 仔细考虑每个药物的独特药理学对于优化多发性硬化症治疗至关重要.
科学领域:
- 神经免疫学 神经免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性硬化症 (MS) 通过炎症驱动的神经元和髓质损伤导致残疾.
- 淋巴细胞和微质激活是MS病理学的关键因素.
- 布鲁顿的氨酸激酶 (BTK) 在B细胞激活和微质前炎症反应中起着关键作用.
研究的目的:
- 探索布鲁顿氨酸激酶 (BTK) 作为多发性硬化症 (MS) 的新型治疗点.
- 讨论与MS治疗相关的BTK抑制剂的复杂药理学.
主要方法:
- 审查BTK在MS发病过程中的作用.
- 分析BTK抑制剂的药理特性,包括结合特异性,中枢神经系统透,半衰期和酶抑制.
- 目前在MS的第三阶段临床试验中BTK抑制剂的概述.
主要成果:
- 通过调节关键的炎症通路,BTK抑制是治疗多发性硬化的一种有希望的策略.
- 在MS中BTK抑制剂的疗效和安全性受到其独特的药理学特征的影响.
- 由于BTK剂的特性变化,需要对BTK剂进行个性化评估.
结论:
- BTK 抑制剂代表了MS治疗的重大进展.
- 了解每个BTK抑制剂的细微药理对于临床应用至关重要.
- 需要对每个药物进行进一步的研究和仔细的临床评估,以确定在MS治疗中最佳的使用.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
176
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
176
Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Enzyme-linked Receptors
78.6K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.6K
Tumor Immunotherapy
530
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
530


